571188-82-4

571188-82-4 - Names and Identifiers

Name	1-Piperazinecarboxylic acid, 4-[6-[(6-bromo-8-cyclopentyl-7,8-dihydro-5-methyl-7-oxopyrido[2,3-d]pyrimidin-2-yl)amino]-3-pyridinyl]-, 1,1-dimethylethyl ester
Synonyms	Palbociclib-016 Palbociclib Intermediate 4 tert-butyl 4-[6-[(6-bromo-8-cyclopentyl-5-methyl-7-oxopyrido[2,3-d]pyrimidin-2-yl)amino]pyridin-3-yl]p tert-butyl 4-{6-[(6-bromo-8-cyclopentyl-5-methyl-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidin-2-yl)amino]pyridin-3-yl}piperazine-1-carboxylat tert-butyl 4-(6-((6-broMo-8-cyclopentyl-5-Methyl-7-oxo-7,8-dihydropyrido[2,3-d]pyriMidin-2-yl)aMino)pyridin-3-yl)piperazine-1-carboxylate 4-[6-(6-BROMO-8-CYCLOPENTYL-5-METHYL-7-OXO-7,8-DIHYDRO-PYRIDO[2,3-D]PYRIMIDIN-2-YLAMINO)-PYRIDIN-3-YL]-PIPERAZINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER 4-[6-[(6-Bromo-8-cyclopentyl-7,8-dihydro-5-methyl-7-oxopyrido[2,3-d]pyrimidin-2-yl)amino]-3-pyridinyl]-1-piperazinecarboxylic acid 1,1-dimethylethyl ester 1-Piperazinecarboxylic acid, 4-[6-[(6-broMo-8-cyclopentyl-7,8-dihydro-5-Methyl-7-oxopyrido[2,3-d]pyriMidin-2-yl)aMino]-3-pyridinyl]-, 1,1-diMethylethyl ester 1-Piperazinecarboxylic acid, 4-[6-[(6-bromo-8-cyclopentyl-7,8-dihydro-5-methyl-7-oxopyrido[2,3-d]pyrimidin-2-yl)amino]-3-pyridinyl]-, 1,1-dimethylethyl ester 4- [6- (6-bromo-8-cyclopentyl-5-methyl-7-oxo-7,8-dihydro-pyrido [2,3-d] pyrimidin -2- ylamino) - pyridine 3-yl] - piperazine-1- carboxylic acid tert-butyl ester
CAS	571188-82-4
EINECS	1592732-453-0

571188-82-4 - Physico-chemical Properties

Molecular Formula	C27H34BrN7O3
Molar Mass	584.51
Density	1.439±0.06 g/cm3(Predicted)
Melting Point	>250℃
Boling Point	720.0±70.0 °C(Predicted)
Solubility	10 mM in DMSO
pKa	5.24±0.10(Predicted)
Storage Condition	2-8°C(protect from light)

571188-82-4 - Preparation solution concentration reference

	1mg	5mg	10mg
1 mM	1.711 ml	8.554 ml	17.108 ml
5 mM	0.342 ml	1.711 ml	3.422 ml
10 mM	0.171 ml	0.855 ml	1.711 ml
5 mM	0.034 ml	0.171 ml	0.342 ml

Last Update：2024-01-02 23:10:35

571188-82-4 - Reference Information

use

pabuxiclib impurity 23 is an impurity of pabuxiclib and is an experimental drug developed by Pfizer to treat breast cancer. It is a selective inhibitor of cyclin-dependent kinases CDK4 and CDK6. In addition, it is derived from 6-bromo-2-chloro-8-cyclopentyl-5-methylpyridine-[2,3-d] pyrimidin-7 (8H)-one for the preparation of pyridyl [2,3-d] pyrimidin-7 (8H)-one derivatives as CDK4 and/or CDK6 inhibitors for the treatment of diseases.

Last Update：2024-04-09 01:59:58